“Integrating functional MR perfusion biomarkers with genomic plasma EBV-DNA and 18FDG-PET/CT metabolic parameters can potentially improve tumor staging, prognostication, and surveillance beyond the traditional AJCC TNM staging system alone.  The Foundation grant proved instrumental in my development as a clinician-scientist. It will support 12 months of dedicated research time, enabling me to collect crucial data for my research on NPC. This data has already directly contributed to my ability to secure additional grant funding. This early success strengthens my resolve to bridge the gap between clinical practice and scientific advancement.”